ATE348803T1 - Tryptase-inhibitoren - Google Patents

Tryptase-inhibitoren

Info

Publication number
ATE348803T1
ATE348803T1 AT02740716T AT02740716T ATE348803T1 AT E348803 T1 ATE348803 T1 AT E348803T1 AT 02740716 T AT02740716 T AT 02740716T AT 02740716 T AT02740716 T AT 02740716T AT E348803 T1 ATE348803 T1 AT E348803T1
Authority
AT
Austria
Prior art keywords
tryptase inhibitors
inhibitors
tryptase
meanings
compounds
Prior art date
Application number
AT02740716T
Other languages
English (en)
Inventor
Thomas Martin
Wolf-Ruediger Ulrich
Thomas Baer
Josef Stadlwieser
Stefan-Lutz Wollin
Karl Zech
Christian P Sommerhoff
Original Assignee
Altana Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Altana Pharma Ag filed Critical Altana Pharma Ag
Application granted granted Critical
Publication of ATE348803T1 publication Critical patent/ATE348803T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Otolaryngology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Pyrrole Compounds (AREA)
AT02740716T 2001-06-19 2002-06-14 Tryptase-inhibitoren ATE348803T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP01114642 2001-06-19

Publications (1)

Publication Number Publication Date
ATE348803T1 true ATE348803T1 (de) 2007-01-15

Family

ID=8177746

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02740716T ATE348803T1 (de) 2001-06-19 2002-06-14 Tryptase-inhibitoren

Country Status (9)

Country Link
US (1) US6962941B2 (de)
EP (1) EP1401809B1 (de)
JP (1) JP2005508871A (de)
AT (1) ATE348803T1 (de)
AU (1) AU2002314165B2 (de)
CA (1) CA2450659A1 (de)
DE (1) DE60216920T2 (de)
ES (1) ES2278928T3 (de)
WO (1) WO2002102771A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI504597B (zh) * 2006-03-16 2015-10-21 Pharmascience Inc 結合於細胞凋亡抑制蛋白（ｉａｐ）之桿狀病毒ｉａｐ重複序列（ｂｉｒ）區域之化合物
JP2011057596A (ja) * 2009-09-09 2011-03-24 Ichimaru Pharcos Co Ltd トリプターゼ活性阻害剤およびその利用
CN110437307B (zh) * 2019-07-26 2020-11-13 暨南大学 一类具抗血栓和脑神经细胞保护作用的水蛭多肽及其应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995032945A1 (en) 1994-06-01 1995-12-07 Arris Pharmaceutical Corporation Compositions and methods for treating mast-cell mediated conditions
AU694275B2 (en) 1994-09-23 1998-07-16 Arris Pharmaceutical Corporation Compositions and methods for treating mast-cell inflammatory conditions
CN1073103C (zh) 1996-07-30 2001-10-17 阿瑞斯药物公司 用于治疗与类胰蛋白酶活性有关的疾病的新化合物和组合物
WO1999012918A1 (fr) 1997-09-05 1999-03-18 Yoshitomi Pharmaceutical Industries, Ltd. Inhibiteur de la tryptase
EP1030844A1 (de) 1997-11-10 2000-08-30 Array Biopharma Inc. Verbindungen, die die aktivität von tryptase hemmen
US6221914B1 (en) 1997-11-10 2001-04-24 Array Biopharma Inc. Sulfonamide bridging compounds that inhibit tryptase activity
WO1999040073A2 (de) * 1998-02-06 1999-08-12 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Tryptase-inhibitoren
EP1060175B1 (de) * 1998-02-06 2004-11-17 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Tryptase-inhibitoren
EP1115731A2 (de) 1998-09-04 2001-07-18 Byk Gulden Lomberg Chemische Fabrik GmbH Neue pyranosen
KR20020016942A (ko) 1999-08-10 2002-03-06 빅 굴덴 롬베르크 케미쉐 파브릭 게엠베하 디아조신-디온 유도체 및 이것의 트립타제 억제제로서 용도
DE19937721A1 (de) 1999-08-10 2001-02-15 Max Planck Gesellschaft Neue Diketopiperazine
EP1216236A1 (de) * 1999-09-14 2002-06-26 Byk Gulden Lomberg Chemische Fabrik GmbH Tryptase inhibitoren
AU783217B2 (en) 1999-12-20 2005-10-06 Altana Pharma Ag Tryptase inhibitors
AU783371B2 (en) 1999-12-20 2005-10-20 Altana Pharma Ag Tryptase inhibitors
ES2225758T3 (es) 2001-01-31 2005-03-16 Altana Pharma Ag Derivdos de diazocina y su uso como agentes inhibidores de la triptasa.
AU2002253026B2 (en) 2001-02-21 2007-08-09 Altana Pharma Ag Tryptase inhibitors
JP2004518736A (ja) 2001-02-21 2004-06-24 アルタナ　ファルマ　アクチエンゲゼルシャフト トリプターゼインヒビター
US20040087792A1 (en) 2001-03-15 2004-05-06 Thomas Martin Tryptase-inhibitors

Also Published As

Publication number Publication date
EP1401809A1 (de) 2004-03-31
CA2450659A1 (en) 2002-12-27
EP1401809B1 (de) 2006-12-20
WO2002102771A1 (en) 2002-12-27
US20040176421A1 (en) 2004-09-09
ES2278928T3 (es) 2007-08-16
AU2002314165B2 (en) 2008-02-21
DE60216920D1 (en) 2007-02-01
JP2005508871A (ja) 2005-04-07
DE60216920T2 (de) 2007-11-15
US6962941B2 (en) 2005-11-08

Similar Documents

Publication Publication Date Title
DE60310576D1 (en) 2-hydroxy-6-phenylphenanthridine als pde-4-hemmer
IS7721A (is) Píperidín-pýrídasón og þalasón sem PDE4 hemlar
ATE353217T1 (de) 3-hydroxy-6-phenylphenanthridine als pde-4 inhibitoren
EA200601587A1 (ru) Новые амидозамещённые гидрокси-6-фенилфенантридины
EA201100689A1 (ru) N-сульфонилпирролы и их применение в качестве ингибиторов гистондезацетилазы
HRP20050228A2 (en) Novel phenanthridines
MX2007005408A (es) Compuestos de aminoquinazolinas.
ES2186874T3 (es) Analogos de m-amidinofenilo como inhibidores del factor xa.
ATE471324T1 (de) Triazolophthalazine
TR200201128T2 (tr) PDE4 inhibitörleri olarak tetrahidrotiyopiranfitalazinon türevleri.
SE9903290D0 (sv) Novel compounds
DE60202669D1 (de) 6-phenylbenzonaphthyidine
ATE269313T1 (de) Tryptase-inhibitoren
DK1244614T3 (da) Tryptase-inhibitorer
ATE348803T1 (de) Tryptase-inhibitoren
ATE508130T1 (de) 3-oxa-10-aza-phenanthrene als pde4- oder pde3/4- inhibitoren
ATE364037T1 (de) Tryptasehemmer
DK1358182T3 (da) Diazocin-derivater og anvendelsen deraf som tryptase-inhibitorer
DE60120398D1 (de) Imidazopyridin-8-one
ATE349427T1 (de) Tryptaseinhibitoren
PL373989A1 (en) Novel benzonaphthyridines
HRP20050293A2 (en) Novel benzonaphthyridines

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties